Staff Directory

Filter By Surname
Filter By Position
Filter By Keyword
Filter By Cancer Type
Search
Professor Fran Balkwill
Professor of Cancer Biology

My key area of interest is in cancer and the tumour microenvironment, especially in ovarian cancer. I study the links between cancer and inflammation and research ways of translating this to clinical trials.

Professor Tyson V. Sharp
Professor of Cellular and Molecular Biology

My group’s work focuses on the role of the tumour suppressor protein LIMD1 and its family members Ajuba and WTIP and how their deregulation in normal tissue contributes to the development of lung, renal and breast cancer.

Dr Katiuscia Bianchi
Senior Lecturer

I am interested in all the strategies cancer cells adopt to proliferate and evade cell death, in order to develop new therapeutic strategies. Specifically, my research focuses on how cancer cell metabolism affects tumour growth and investigating how inflammation can drive malignant transformation.

Dr Andrejs Braun
Senior Lecturer

I am interested in the mechanisms of tumour clearance in response to targeted therapy with monoclonal antibodies. I work on antibody therapies for lymphoma and the epigenetics of somatic hypermutation in normal and malignant B cells.

Dr Angus James Cameron
Senior Lecturer

My research focuses on kinases regulating cancer cell growth and motility to understand how and when to target them with drugs. My group is currently examining the role of the PKN kinases in malignant progression.

Dr Pedro R. Cutillas
Reader in Cell Signalling and Proteomics

My research group uses unique proteomics and computational approaches to understand how cell signalling pathways driven by the activity of protein kinases contribute to the development of cancer. Increasing this knowledge will be invaluable in advancing personalised cancer therapies.

Dr Susana Godinho
Senior Lecturer

Our research group focuses on understanding how centrosome amplification impacts tumour progression and how we can target cells with amplified centrosomes to develop new cancer therapies.

Professor Richard Grose
Professor of Cancer Cell Biology

We are interested in how cancer cells interact with each other and the microenvironment. We investigate how cancer cells develop resistance to therapies and design drug combination approaches to overcome this.

Dr Gunnel Halldén
Reader in Cancer Gene Therapy

The research in our team is focused on the development of novel treatment strategies to target prostate and pancreatic cancers using genetically modified viruses that target, replicate and kill cancer cells but leave normal cells unharmed.

Dr Zuzana Horejsi
Lecturer

My lab focuses on discovering functions of phosphorylation induced by damaged DNA in normal and cancer cells, and investigating the role of different phosphorylation events in cancer development.

Dr Li Jia
Senior Lecturer

I am interested in studying the effects of the inflammatory microenvironment on disease progression and resistance to treatment in haematological malignancies with emphasis on survival and mechanisms of treatment resistance in chronic lymphocytic leukaemia and B cell lymphoma.

Dr Stéphanie Kermorgant
Reader in Cellular Oncology

We study the role of growth factor receptor signalling and intracellular trafficking (movement inside cells) in tumour growth and metastasis in the view of improving cancer therapy.

Dr Sergey Krysov
Senior Lecturer

My studies concentrate on the immunogenetics of human B cell malignancies, such as chronic lymphocytic leukaemia, follicular lymphoma and the role for B cell receptor in the development of B cell lymphoma and leukaemia.

Dr Sarah Martin
Reader; Director of Graduate Studies for Research (BCI)

Our research is based on exploiting DNA repair defects in cancer for the identification of new personalised therapies. We use compound and siRNA screening to identify new therapeutics for tumours based on their specific DNA repair status.

Dr Paulo Ribeiro
Senior Lecturer

Our research group is interested in uncovering the molecular mechanisms regulating tissue growth, invasion and metastasis using the fruit fly Drosophila melanogaster as a genetically tractable model organism.

Dr John Riches
Clinical Senior Lecturer

My major research interest is understanding the metabolism of chronic lymphocytic leukaemia and lymphoma with the aim that this will underpin the development of the next generation of anti-metabolic drugs for these diseases.

Dr Kevin Rouault-Pierre
Lecturer

My main research interests are in haematopoietic stem cells (HSCs) and leukemic initiating cells. I seek to understand how intrinsic and extrinsic signals are integrated by normal and malignant stem cells.

Dr Chinedu (Anthony) Anene

My current project aim is to develop novel molecular biomarkers for prostate cancer, a leading cause of male specific cancer death.

Dr Katia Bouchekioua-Bouzaghou

My project aims to investigate how resistance mechanisms are acquired to a number of CDK4/6 inhibitors and to pinpoint new targets for therapy.

Dr David Britton

My project is focused on determining how certain proteins enable acute myeloid leukaemia blasts to acquire or have intrinsic resistance to chemotherapy, with the aim to identify suitable pharmaceutical alternatives to combat resistance.

Dr Pedro Casado-Izquierdo

My work is based on studying signalling networks in AML primary samples in order to predict responses to kinase inhibitors.

Dr Natasha Clayton

Investigating the intracellular signalling mechanisms underlying the development of resistance to therapeutic RTK inhibitors, particularly in FGFR-driven cancers.

Dr Marta Crespi-Sallan

My research is focused on describing the mechanisms underlying Lamin B1 nuclear disassembly in B-cell normal development and how a dis-regulated Lamin B1 removal pathway could lead to several haematological malignancies within the germinal centre in secondary lymph organs.

Dr Danilo Cucchi

My main research is focused on the identification of DNA damage signatures that predict response to immune checkpoint blockade. I am also interested in the role of metabolism in the biology of both cancer cells and immune cells.

Dr Gabriela d’Amico Lago

My work is focused on understanding the roles of kinase and non-kinase motifs of FAK in controlling physiological angiogenesis in vivo. Overall my goal is to understand how to best control tumour blood vessels in the regulation of cancer.

Dr Jesus Gomez Escudero

I am involved in some projects that are focused in the stroma components of a tumour, particularly the endothelial vessels, and its potential role in some key processes including chemotherapy or metastasis.

Dr Daniel Friedman

My research is focused on investigating the crosstalk between immune cell subsets in the tumour microenvironment in pancreatic ductal adenocarcinoma.

Dr Michelle Goulart

My research is focused in understanding the tumour-stroma interactions in pancreatic cancer and the identification of potential biomarkers.

Dr Damien Goutte-Gattat

I am using fruit flies to investigate the role of tumour heterogeneity in the development of glioblastoma and the acquisition of resistance to chemotherapy.

Dr Miguel Hermida

My project studies the influence that the loss of the tumour suppressor protein LIMD1 has in renal and lung cancers by identifying selective drugs, targets and the cell signalling involved in order to improve the current therapy.

Dr Sara Farrah Heuss

My work focuses on c-Met signalling on endosomes in pancreatic cancer, and to evaluate how it can be exploited to benefit pancreatic cancer patients.

Dr Maruan Hijazi-Vega

My work is focused on producing systematic classification of phosphorylation sites detectable by mass spectrometry that will provide new insights into the complexity and topology of kinase signalling.

Dr Oscar Maiques

My research will focus on studying Myosin II function during melanoma progression and its cross-talk with inflammatory and immune responses.

Dr Marie Nollet

Our group has shown that internalised c-Met traffics through endomembranes positive for LC3B and Beclin1. Furthermore, c-Met sustains signalling from Autophagy Related Endomembranes, ARE. We hypothesised therefore that the AREs supporting c-Met trafficking and signalling belong to a novel non-canonical pathway.

Dr Jose Orgaz

My research focuses on cutaneous melanoma biology, a highly aggressive and metastatic cancer. I aim to get more insights into signalling pathways underlying melanoma progression and responses to current therapies. In particular, I am interested in the role of the actomyosin cytoskeleton in drug resistance.

Dr Irene Rodriguez-Hernandez

My research is focused on investigating the role of ROCK-Myosin II in tumour and metastasis initiation.

Dr Kunal Shah

I am studying how the tumour suppressor gene LIMD1 functions in the microRNA pathway, a gene regulatory pathway that is often dysregulated in cancer.

Dr Vera Silva

I am trying to understand how new drugs in combination with carboplatin can help bypass therapy resistance in ovarian cancer.

Dr Filomena Spada

My research involves using mass cytometry based analysis to characterise the interaction, activation, and signalling capacity of B and T-cells in CLL and other B-cell malignancies.

Dr Kirtiman Srivastava

My research is focused on pancreatic ductal adenocarcinomas (PDAC), primarily the identification and quantification of PDAC biomarkers in patient urine samples and understanding the biology of cancerous transformation.